| Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis V Diaby, K Campbell, R Goeree Operations Research for Health Care 2 (1-2), 20-24, 2013 | 201 | 2013 |
| Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis G Adunlin, V Diaby, H Xiao Health Expectations 18 (6), 1894-1905, 2015 | 177 | 2015 |
| A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer V Diaby, R Tawk, V Sanogo, H Xiao, AJ Montero Breast cancer research and treatment 151 (1), 27-40, 2015 | 114 | 2015 |
| How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide V Diaby, R Goeree Expert review of pharmacoeconomics & outcomes research 14 (1), 81-99, 2014 | 102 | 2014 |
| Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward R Baltussen, K Marsh, P Thokala, V Diaby, H Castro, I Cleemput, M Garau, ... Value in Health 22 (11), 1283-1288, 2019 | 83 | 2019 |
| Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial V Diaby, G Adunlin, AJ Montero Pharmacoeconomics 32 (2), 101-108, 2014 | 74 | 2014 |
| Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective C Tannenbaum, V Diaby, D Singh, S Perreault, M Luc, HM Vasiliadis Drugs & aging 32 (4), 305-314, 2015 | 60 | 2015 |
| Multicriteria decision analysis in oncology G Adunlin, V Diaby, AJ Montero, H Xiao Health Expectations 18 (6), 1812-1826, 2015 | 44 | 2015 |
| Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? R Goeree, V Diaby Best practice & research Clinical gastroenterology 27 (6), 831-844, 2013 | 44 | 2013 |
| Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States V Diaby, G Adunlin, AA Ali, SB Zeichner, G de Lima Lopes, CG Kohn, ... Breast cancer research and treatment 160 (1), 187-196, 2016 | 33 | 2016 |
| Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion V Diaby, R Goeree, J Hoch, U Siebert Expert review of pharmacoeconomics & outcomes research 15 (1), 13-19, 2015 | 29 | 2015 |
| Preventing unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada M Boulin, V Diaby, C Tannenbaum PloS one 11 (9), e0162951, 2016 | 27 | 2016 |
| An application of a proposed framework for formulary listing in low-income countries V Diaby, J Lachaine Applied health economics and health policy 9 (6), 389-402, 2011 | 23 | 2011 |
| Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer V Diaby, G Adunlin, SB Zeichner, K Avancha, G Lopes, S Gluck, ... Breast cancer research and treatment 147 (2), 433-441, 2014 | 20 | 2014 |
| Value assessment frameworks in the United States: a call for patient engagement V Diaby, AA Ali, AJ Montero PharmacoEconomics-Open 3 (1), 1-3, 2019 | 16 | 2019 |
| Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data NA Limdi, LH Cavallari, CR Lee, WB Hillegass, AM Holmes, TC Skaar, ... The pharmacogenomics journal 20 (5), 724-735, 2020 | 14 | 2020 |
| Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives V Diaby, AA Ali, KJ Williams, K Ezendu, E Soto-Perez-de-Celis, ... Breast cancer research and treatment 166 (3), 951-963, 2017 | 14 | 2017 |
| ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare V Diaby, V Sanogo, KR Moussa Expert review of pharmacoeconomics & outcomes research 16 (1), 141-147, 2016 | 14 | 2016 |
| Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial V Diaby, G Adunlin, AA Ali, R Tawk Breast cancer research and treatment 146 (3), 669-673, 2014 | 12 | 2014 |
| Timing, costs, and survival outcome of specialty palliative care in medicare beneficiaries with metastatic non–small-cell lung cancer J Huo, YR Hong, K Turner, V Diaby, C Chen, J Bian, R Grewal, DJ Wilkie JCO Oncology Practice 16 (12), e1532-e1542, 2020 | 11 | 2020 |
